drugset / Trial / NCT00035321

The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression

NCT00035321

Phase 3 Completed 600 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purposes of this study are to determine: * Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression. * The safety of olanzapine plus fluoxetine in combination, plus and any side effects that might be associated with the combination. * The effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine alone.

Timeline

Start
2002-04
Primary completion
Completion
2005-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 50 mg Oral
Subject Olanzapine Small molecule 6 mg Oral
Subject Olanzapine Small molecule 18 mg Oral